Neoleukin Investor R&D Showcase - AACR 2020
http://investor.neoleukin.com/events,
June 23, 2020
The event will feature an overview of presentations at the American Association for Cancer Research (AACR) Virtual Annual Meeting II as well as commentary from experts in the field of protein design and clinical development of IL-2 therapies.
To RSVP to the webcast please click here!
Speakers will include:
 |
Jonathan Drachman, M.D. – Chief Executive Officer of Neoleukin |
 |
David Baker, Ph.D. – Co-founder of Neoleukin and Director of the University of Washington Institute for Protein Design, UW School of Medicine professor of biochemistry and a Howard Hughes Medical Institute investigator |
 |
Michael Dougan, M.D., Ph.D. – Assistant Professor of Medicine at Harvard Medical School and an assistant in Medicine, Division of Gastroenterology at Massachusetts General Hospital |
 |
Nizar Tannir, MD, FACP – Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, MD Anderson Cancer Center |
Neoleukin Therapeutics
[NLTX]
$440 MM MCap
Lead program NL-201: is a dual-acting IL-2 and IL-15 agonist immunotherapy for cancer, designed to improve tolerability and activity by eliminating the alpha receptor binding interface (IND completed 4Q20). First de novo protein therapeutic ever created. [more information]